1. Scrip
  2. >>Business
  3. >>Deals

Recent Tech Transfer Deals, June 2012

 
• By Deanna Kamienski, Beth Allan, Amanda Micklus, Andrea Mancini, and Maureen Riordan

START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in the fields of in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.

Dako to develop new cancer tests based on the MET4 antibody discovered by Van Andel researchers

The Van Andel Research Institute (VARI), which is supported by the Van Andel Institute and focuses on biomedical research...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal

 
• By Joseph Haas

Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Chiesi Moves Into Rare Disease Gene Therapy Under Pact With Arbor

 
• By Joseph Haas

Chiesi and the Boston-area biotech will co-develop a CRISPR-Cas gene-editing therapy for primary hyperoxaluria type 1. They hope to provide a curative therapy for the rare disease.

Deal Watch: Clywedog, Barinthus To Merge With Focus On Diabetes, Celiac Disease

 
• By Joseph Haas

Plus deals involving Klotho/Turn, BioLineRx/Hemispherian, Dogwood/Serpin, Harrow/Melt, Gossamer/Respira, Lilly/Prellis, BI/TegMine and more.

More from Business

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 
• By Alaric DeArment

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By Andy Smith

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.